1. |
Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer, 2006, 6(8): 637-645.
|
2. |
Stewart F. Roles of mesenchymal-epithelial interactions and hepatocyte growth factorscatter factor (HGF-SF) in placental development. Rev Reprod, 1996, 1(3): 144-148.
|
3. |
Walentinsson A, Helou K, Wallenius V, et al. Independent amplification of two gene clusters on chromosome 4 in rat endometrial cancer: identification and molecular characterization. Cancer Res, 2001, 61(22): 8263-8273.
|
4. |
Lee SJ, Seol HJ, Lee HW, et al. Gene silencing of c-Met leads to brain metastasis inhibitory effects. Clin Exp Metastasis, 2013, 30(7): 845-854.
|
5. |
Laser-Azogui A, Diamant-Levi T, Israeli S, et al. Met-induced membrane blebbing leads to amoeboid cell motility and invasion. Oncogene, 2014, 33(14): 1788-1798.
|
6. |
Noguchi E, Saito N, Kobayashi M, et al. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep, 2015, 11(5): 3423-3431.
|
7. |
Madoz-Gúrpide J, Zazo S, Chamizo C, et al. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med, 2015, 29(13): 282.
|
8. |
Matsumoto K, Umitsu M, De Silva DM, et al. HGF-MET in cancer progression and biomarker discovery. Cancer Sci, 2017, 108(3): 296-307.
|
9. |
Nakamura T. Hepatocyte growth factor as mitogen, motogen and morphogen, and its roles in organ regeneration. Princess Takamatsu Symp, 1994, 24: 195-213.
|
10. |
Jiang WG, Hallett MB, Puntis MC. Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastasis. Br J Surg, 1993, 80(11): 1368-1373.
|
11. |
Weidner KM, Hartmann G, Sachs M, et al. Properties and functions of scatter factor/hepatocyte growth factor and its receptor c-Met. Am J Respir Cell Mol Biol, 1993, 8(3): 229-237.
|
12. |
Kwon Y, Godwin AK. Regulation of HGF and c-MET Interaction in normal ovary and ovarian cancer. Reprod Sci, 2017, 24(4): 494-501.
|
13. |
姚建锋, 孙学军, 阎立昆, 等. c-Met 在结直肠癌细胞株中的表达及其配体肝细胞生长因子对 SW480 细胞株增殖和侵袭能力的影响. 中国普外基础与临床杂志, 2015, 22(11): 1314-1318.
|
14. |
Osada S, Matsui S, Komori S, et al. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology, 2010, 57(97): 76-80.
|
15. |
Feng Y, Thiagarajan PS, Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol, 2012, 7(2): 459-467.
|
16. |
Ang CS, Sun MY, Huitzil-Melendez DF, et al. c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival. Anticancer Res, 2013, 33(8): 3241-3245.
|
17. |
Shoji H, Yamada Y, Taniguchi H, et al. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. CancerSci, 2014, 105(8): 1002-1007.
|
18. |
Gardner FP, Serie DJ, Salomao DR, et al. c-MET expression in primary and liver metastases in uveal melanoma. Melanoma Res, 2014, 24(6): 617-620.
|
19. |
Herynk MH, Zhang J, Parikh NU, et al. Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J Exp Ther Oncol, 2007, 6(3): 205-217.
|
20. |
Osada S, Yoshida K. Application of biological study for met expression to cancer therapy. Anticancer Agents Med Chem, 2010, 10(1): 58-63.
|
21. |
Abou-Bakr AA, Elbasmi A. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J Oncolog, 2013, 1(14): 28-34.
|
22. |
Noguchi E, Saito N, Kobayashi M, et al. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep, 2015, 11(5): 3423-3431.
|
23. |
Schweiger T, Starkl V, Glueck O, et al. Clinical impact of c-MET expression and mutational status in patients with colorectal cancer lung metastases. Eur J Cardiothorac Surg, 2016, 49(4): 1103-1111.
|
24. |
Li M, Xin X, Wu T, et al. HGF and c-Met in pathogenesis of endometrial carcinoma. Front Biosci (Landmark Ed), 2015, 1(20): 635-643.
|
25. |
Shali H, Ahmadi M, Kafil HS, et al. IGF1R and c-met as therapeutic targets for colorectal cancer. Biomed Pharmacother, 2016, 82: 528-536.
|
26. |
Stabile LP, Rothstein ME, Gubish CT, et al. Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF. J Thorac Oncol, 2014, 9(9): 1285-1293.
|
27. |
Bradley CA, Dunne PD, Bingham V, et al. Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget, 2016, 7(48): 78932-78945.
|
28. |
Hass R, Jennek S, Yang Y, et al. c-Met expression and activity in urogenital cancers novelaspects of signal transduction and medical implications. Cell Commun Signal, 2017, 15(1): 10.
|
29. |
Mungunsukh O, Lee YH, Bottaro DP, et al. The hepatocyte growth factor isoform NK2 activates motogenesis and survival but not proliferation due to lack of Akt activation. Cell Signal, 2016, 28(8): 1114-1123.
|
30. |
Zhang J, Babic A. Regulation of the MET oncogene: molecular mechanisms. Carcinogenesis, 2016, 37(4): 345-355.
|